2013-01-11 07:54:29 -
Lysaker, Norway, 11 January 2013: Pronova BioPharma (OSE: PRON.OL) has been
informed that Omacor and Zodin have been placed on a negative reimbursement list
in Greece as part of cost containment measures that is currently being
implemented. The negative reimbursement list includes several hundred
pharmaceutical products and was put in place in December.
Pronova and its partners in Greece, Abbott Laboratories and Grupo Ferrer, have
appealed the decision in order to secure continued good access to Omacor and
Zodin for Greek patients.
Greece is among the 8 largest markets for Pronova, and represents around 4
percent of Pronova's total sales. Pronova has sales to 61 countries.
Pronova BioPharma ASA
VP Investor Relations and Communications
Tel: +47 40 46 81 10
This information is subject of the disclosure requirements pursuant to section
the Norwegian Securities Trading Act.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Pronova BioPharma ASA via Thomson Reuters ONE